(CBT) Cabot - Ratings and Ratios
Carbon Black, Silica, Elastomer, Aerogel, Nanotube
Dividends
| Dividend Yield | 2.76% |
| Yield on Cost 5y | 4.69% |
| Yield CAGR 5y | 4.82% |
| Payout Consistency | 90.5% |
| Payout Ratio | 24.5% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 30.1% |
| Value at Risk 5%th | 44.8% |
| Relative Tail Risk | -9.55% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.68 |
| Alpha | -52.63 |
| CAGR/Max DD | -0.03 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.399 |
| Beta | 0.816 |
| Beta Downside | 0.587 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.78% |
| Mean DD | 15.91% |
| Median DD | 13.67% |
Description: CBT Cabot November 07, 2025
Cabot Corporation (NYSE: CBT) is a specialty chemicals and performance materials firm organized into two primary segments: Reinforcement Materials, which supplies carbon black for tire reinforcement and industrial elastomers, and Performance Chemicals, which produces a portfolio of specialty carbons, fumed silica/alumina, aerogels, masterbatches, inkjet colorants, carbon nanotubes, and related metal oxides.
The company’s carbon black business remains tightly linked to global tire demand-an industry that is projected to grow ~3% yr-1 through 2028, driven by vehicle production rebounds and stricter fuel-efficiency standards. On the performance-chemicals side, Cabot benefits from accelerating electric-vehicle (EV) battery production; its fumed alumina and silica are key conductive additives for both lead-acid and lithium-ion cells, a market that has expanded at roughly 15% CAGR over the past three years.
Financially, Cabot reported FY 2023 revenue of $2.8 billion with an adjusted EBITDA margin of 12.5%, and the firm has signaled FY 2024 guidance targeting modest top-line growth (≈2-3%) while managing raw-material cost volatility tied to petroleum-derived feedstocks. The company’s geographic footprint-distribution across the Americas, EMEA, and APAC-helps mitigate regional demand cycles but also exposes it to currency fluctuations, especially the euro and yuan.
For analysts seeking a deeper quantitative view of Cabot’s valuation dynamics, the ValueRay platform offers granular, real-time metrics and scenario analyses that can sharpen the assessment of its exposure to EV-battery demand and commodity price swings.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (331.0m TTM) > 0 and > 6% of Revenue (6% = 222.8m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA -1.88pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 22.43% (prev 20.87%; Δ 1.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 665.0m > Net Income 331.0m (YES >=105%, WARN >=100%) |
| Net Debt (976.0m) to EBITDA (804.0m) ratio: 1.21 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (53.4m) change vs 12m ago -3.26% (target <= -2.0% for YES) |
| Gross Margin 25.40% (prev 24.30%; Δ 1.09pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 98.06% (prev 106.8%; Δ -8.77pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.55 (EBITDA TTM 804.0m / Interest Expense TTM 76.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.90
| (A) 0.22 = (Total Current Assets 1.57b - Total Current Liabilities 740.0m) / Total Assets 3.84b |
| (B) 0.48 = Retained Earnings (Balance) 1.85b / Total Assets 3.84b |
| (C) 0.17 = EBIT TTM 650.0m / Avg Total Assets 3.79b |
| (D) 0.72 = Book Value of Equity 1.54b / Total Liabilities 2.15b |
| Total Rating: 4.90 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 67.90
| 1. Piotroski 7.0pt |
| 2. FCF Yield 9.00% |
| 3. FCF Margin 10.53% |
| 4. Debt/Equity 0.79 |
| 5. Debt/Ebitda 1.21 |
| 6. ROIC - WACC (= 4.37)% |
| 7. RoE 22.54% |
| 8. Rev. Trend -67.63% |
| 9. EPS Trend 57.12% |
What is the price of CBT shares?
Over the past week, the price has changed by +1.88%, over one month by -1.37%, over three months by -19.15% and over the past year by -40.25%.
Is CBT a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 2
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the CBT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 67 | 3.8% |
| Analysts Target Price | 67 | 3.8% |
| ValueRay Target Price | 56.1 | -13.1% |
CBT Fundamental Data Overview December 03, 2025
P/E Trailing = 10.5183
P/E Forward = 9.6246
P/S = 0.9073
P/B = 2.1354
P/EG = 1.83
Beta = 0.89
Revenue TTM = 3.71b USD
EBIT TTM = 650.0m USD
EBITDA TTM = 804.0m USD
Long Term Debt = 856.0m USD (from longTermDebt, last quarter)
Short Term Debt = 110.0m USD (from shortTermDebt, last quarter)
Debt = 1.22b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 976.0m USD (from netDebt column, last quarter)
Enterprise Value = 4.34b USD (3.37b + Debt 1.22b - CCE 239.0m)
Interest Coverage Ratio = 8.55 (Ebit TTM 650.0m / Interest Expense TTM 76.0m)
FCF Yield = 9.00% (FCF TTM 391.0m / Enterprise Value 4.34b)
FCF Margin = 10.53% (FCF TTM 391.0m / Revenue TTM 3.71b)
Net Margin = 8.91% (Net Income TTM 331.0m / Revenue TTM 3.71b)
Gross Margin = 25.40% ((Revenue TTM 3.71b - Cost of Revenue TTM 2.77b) / Revenue TTM)
Gross Margin QoQ = 24.81% (prev 26.44%)
Tobins Q-Ratio = 1.13 (Enterprise Value 4.34b / Total Assets 3.84b)
Interest Expense / Debt = 1.65% (Interest Expense 20.0m / Debt 1.22b)
Taxrate = 53.85% (63.0m / 117.0m)
NOPAT = 300.0m (EBIT 650.0m * (1 - 53.85%))
Current Ratio = 2.13 (Total Current Assets 1.57b / Total Current Liabilities 740.0m)
Debt / Equity = 0.79 (Debt 1.22b / totalStockholderEquity, last quarter 1.54b)
Debt / EBITDA = 1.21 (Net Debt 976.0m / EBITDA 804.0m)
Debt / FCF = 2.50 (Net Debt 976.0m / FCF TTM 391.0m)
Total Stockholder Equity = 1.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.63% (Net Income 331.0m / Total Assets 3.84b)
RoE = 22.54% (Net Income TTM 331.0m / Total Stockholder Equity 1.47b)
RoCE = 27.96% (EBIT 650.0m / Capital Employed (Equity 1.47b + L.T.Debt 856.0m))
RoIC = 11.20% (NOPAT 300.0m / Invested Capital 2.68b)
WACC = 6.83% (E(3.37b)/V(4.58b) * Re(9.02%) + D(1.22b)/V(4.58b) * Rd(1.65%) * (1-Tc(0.54)))
Discount Rate = 9.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.17%
[DCF Debug] Terminal Value 72.85% ; FCFE base≈415.0m ; Y1≈371.2m ; Y5≈315.1m
Fair Price DCF = 90.83 (DCF Value 4.80b / Shares Outstanding 52.9m; 5y FCF grow -13.04% → 3.0% )
EPS Correlation: 57.12 | EPS CAGR: 7.64% | SUE: 0.0 | # QB: 0
Revenue Correlation: -67.63 | Revenue CAGR: -1.95% | SUE: -1.81 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.67 | Chg30d=-0.374 | Revisions Net=-2 | Analysts=5
EPS current Year (2026-09-30): EPS=6.52 | Chg30d=-1.256 | Revisions Net=-4 | Growth EPS=-10.1% | Growth Revenue=-3.2%
EPS next Year (2027-09-30): EPS=7.17 | Chg30d=-1.204 | Revisions Net=-4 | Growth EPS=+10.0% | Growth Revenue=+2.9%
Additional Sources for CBT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle